C4 Therapeutics, Inc.

CCCC · NASDAQ

Company research

C4 Therapeutics, Inc. (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, dedicated to advancing targeted protein degradation (TPD) science to develop a new generation of small-molecule medicines for oncology, neurodegenerative disorders, and other serious diseases. Founded in 2015, the company leverages its proprietary TORPEDO® platform to design and optimize bifunctional degrader molecules — including MonoDACs and BiDACs — that harness the body's natural protein recycling machinery to selectively eliminate disease-causing proteins, with the potential to overcome drug resistance and address historically "undruggable" targets. Its lead candidate, Cemsidomide (CFT7455), an orally bioavailable MonoDAC degrader targeting IKZF1/3, is advancing through Phase 1/2 clinical trials for multiple myeloma and non-Hodgkin lymphomas, while additional pipeline assets including CFT8634, CFT1946, and CFT8919 target solid tumors and genetically defined cancers. C4 Therapeutics has established strategic collaborations with major pharmaceutical partners including F. Hoffmann-La Roche, Biogen, Merck KGaA, and Calico Life Sciences, supporting the broad application of its degrader platform across multiple therapeutic areas.

Research reports

AInvest · February 2, 2026C4 Therapeutics: A Value Investor's Assessment of a High-Risk, High-Potential Platform

AI-assisted, editorially reviewed value-investing note arguing that C4’s worth lies in the long-term option value of its TORPEDO protein-degrader platform and lead asset cemsidomide, supported by a 2025 $125M financing that extends cash runway to 2028 and validated by collaborations with Roche, Betta and Pfizer, while emphasizing that the thesis is high-risk due to potential clinical setbacks, chemistry/manufacturing (CMC) challenges, and execution risks around partnerships and eventual commercialization.